Navigation Links
Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP
Date:7/24/2014

SAN DIEGO, July 24, 2014 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, reported interim results in a Phase 2a single-arm, open-label trial where ASONEP™ is being investigated as a treatment for metastatic renal cell carcinoma (RCC) in patients that have failed at least one therapy involving a VEGF inhibitor (e.g., Sutent®/ sunitinib maleate) and no more than one mTOR inhibitor (e.g., Afinitor®/everolimus), with a maximum of three failed treatments in all. This patient population is considered "last line," and the literature suggests cancer progression in this population within a one-to-two month time frame.

Lpath has enrolled 26 patients in the study. ASONEP has a favorable safety profile thus far, with no serious adverse events (SAEs) deemed to be drug-related.

The first 17 patients were initiated at a dose of 15 mg/kg. Of these "lower-dose" patients:  7 had progressive disease at or before the end of four months; 8 were progression-free at the four-month mark (with 1 of these patients deemed a partial responder per Response Evaluation Criteria in Solid Tumors (RECIST) criteria and with 3 of these patients experiencing reduced tumor volume, but not enough to be categorized as a RECIST-based partial responder); and 2 exited the study due to SAEs unrelated to the drug prior to the four-month mark (and are not considered evaluable). Notably, of the 8 patients that were stable or better as of month four, 2 are now in their fifteenth month on the study, 1 is in month thirteen, and 1 is in month ten. An additional patient was stable through month seven, but then missed six treatments during a vacation, and shortly thereafter progressed.

The next 9 patients were initiated at a dose of 24 mg/kg. Of these higher-dose patients: 4 had progressive disease at or before
'/>"/>

SOURCE Lpath
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lpath Withdraws From Pfizers Process to Assign iSONEP Rights
2. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
3. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
4. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
5. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
6. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
7. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
8. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
9. Luminex Corporation Reports First Quarter 2012 Results
10. Hospira Reports First-Quarter 2012 Results
11. Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... June 1, 2015 CEFALY Technology , ... stimulation device specifically authorized for use prior to the ... a new PET trial showing that the Cefaly device ... brain in migraine patients, namely the orbitofrontal cortex and ... scan, which is an imaging test of the brain, used a radioactive ...
(Date:6/1/2015)... SETAUKET, N.Y. , June 1, 2015 /PRNewswire/ ... (NASDAQ: HRTX ) today announced positive, top-line ... study.  MAGIC evaluated the efficacy and safety of ... candidate SUSTOL ® (granisetron injection, extended release) ... intravenous (IV) neurokinin-1 (NK 1 ) receptor antagonist ...
(Date:6/1/2015)... 2015   OTC Markets Group Inc. ... financial marketplaces for 10,000 U.S. and global securities, ... Diego -based biopharmaceutical company, on its NASDAQ ... public venture market for entrepreneurial and development stage ... "We,re happy to congratulate OncoSec ...
Breaking Medicine Technology:New Study Shows CEFALY Returns Normal Metabolic Activity to Brain Areas in Migraine Patients 2New cancer therapy study results - MAGIC Trial 2OTC Markets Group Congratulates OncoSec Medical on NASDAQ Listing 2
... and drug withdrawal, CHICAGO, May 15, 2007 /PRNewswire/ ... and physicians commissioned by the National,Headache Foundation and ... migraine patients are currently taking potentially,addictive medications that ... by the U.S. Food and Drug Administration for ...
... , LONDON, UK and ATLANTA, US, May 14, ... Inc. (NASDAQ:SCRX) today,announce the successful completion of the ... a calcium ,channel blocking agent for the treatment ... the new Sular formulation is,bioequivalent to Sciele's currently ...
Cached Medicine Technology:Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 2Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 3Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 4Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 5Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 6SkyePharma and Sciele Pharma Announce Successful Completion of New,Sular Formulation Clinical Trial Programme 2SkyePharma and Sciele Pharma Announce Successful Completion of New,Sular Formulation Clinical Trial Programme 3
(Date:6/2/2015)... June 02, 2015 Colleen’s Dream Foundation ... granted $70,000 to the UNMC to support ovarian cancer research ... Cundiff, a member of the Colleen’s Dream Foundation Board of ... the biggest to date for Colleen’s Dream Foundation and they ... Omaha. , “Dr. Wang is a rising star in the ...
(Date:6/2/2015)... June 02, 2015 While the movie ... of comic books, comic books themselves are stepping into ... Uniting Nations plans to produce educational comics in multiple ... Goals for Sustainable Development - an international effort to ... hunger, health, education, sustainable energy, inequality, climate change and ...
(Date:6/2/2015)... 02, 2015 Pacifica Graduate Institute ... up by current and former students to honor the ... member from 2002 until his death in 2013. His ... depth of feeling, as well as his passion for ... as an analyst, teacher, and writer were felt in ...
(Date:6/1/2015)... (PRWEB) June 02, 2015 The ... Lynn Lester as a 2015-2016 inductee into its ... with this prestigious distinction for leadership in business. NAPW ... women, boasting more than 700,000 members and over 200 ... Lester with this prestigious award,” said NAPW President Star ...
(Date:6/1/2015)... (PRWEB) June 02, 2015 The ... Linda Cade as a 2015-2016 inductee into its ... with this prestigious distinction for leadership in business. NAPW ... women, boasting more than 700,000 members and over 200 ... with this important honor,” said NAPW President Star Jones. ...
Breaking Medicine News(10 mins):Health News:Colleen’s Dream Foundation Grants $70,000 to the University of Nebraska Medical Center (UNMC) to Support Ovarian Cancer Research 2Health News:Colleen’s Dream Foundation Grants $70,000 to the University of Nebraska Medical Center (UNMC) to Support Ovarian Cancer Research 3Health News:Can Comics Help the United Nations Save the World? 2Health News:Can Comics Help the United Nations Save the World? 3Health News:Pacifica Graduate Institute - Mythological Studies Students Establish Memorial Scholarship to Honor Dr. V. Walter Odajnyk 2Health News:Pacifica Graduate Institute - Mythological Studies Students Establish Memorial Scholarship to Honor Dr. V. Walter Odajnyk 3Health News:National Association of Professional Women Inducts Lynn Lester, Director of Clinical Operations/CEO, Recovery Treatment Center, Into its VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Linda Cade, Senior Product Manager at Sage, Into its VIP Professional Woman of the Year Circle 2
... RIDGE, N.J., Oct. 19 VioQuest,Pharmaceuticals (OTC ... focused on acquiring, developing and,commercializing targeted cancer ... data in poster presentations pertaining to VQD-002 ... and Cancer Therapeutics",International Conference sponsored by the ...
... CSV ) today announced plans to release 2007 third quarter ... conjunction with the,release, Carriage Services has scheduled a conference call, ... 2, 2007 at 10:00,a.m. eastern time. What: ... When: Friday, November 2, 2007 ...
... Amedisys, Inc.,(Nasdaq: AMED or the "Company"), one of ... intends to release its financial,results for the quarter ended ... Company will also host a conference call with the,investment ... To participate in the conference call, please dial 800-683-1525,(Domestic) ...
... US Oncology Holdings, Inc. and its,operating subsidiary, US ... on Thursday, November 8, 2007. A conference ... at 10:00,a.m., EST, for the company,s bondholders following ... representatives of US Oncology,s management,team will discuss the ...
... poor, uninsured,women in Pennsylvania will no longer have ... Prevention Project has ended. "Poor,women are going to ... funding for this critical program," declared Dorothy Mann, ... "We had a,Democratic supporter who worked with a ...
... Association of,Dental Plans (NADP) calls on Congress and the ... Program (CHIP).,Specifically, NADP urges prompt action to enact the ... bill., In letters to congressional health policy leaders, ... Dental services should be a mandatory CHIP benefit. ...
Cached Medicine News:Health News:VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting 2Health News:VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting 3Health News:VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting 4Health News:VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting 5Health News:Carriage Services Announces Third Quarter Earnings Release and Conference Call Schedule 2Health News:Amedisys to Host Conference Call to Discuss Third Quarter Financial Performance and Operating Results 2Health News:Pa. Funding for Cervical Cancer Prevention Services Ends 2Health News:NADP Calls on Congress and the White House to Work Together to Cover Children's Dental Health 2
... Savant offers several different two-stage, oil-sealed, rotary ... freeze drying applications. Each pump comes complete ... Kit) and and Oil Mist Filter (EMF-10). ... full gas ballast to keep the oil ...
Produces vacuum pressures required for 96 well kits...
Inquire...
... The Perfect Single Vac ... one 96-well plate in 30 ... with an "open/closed" switch and ... for easy operation. contains vacuum ...
Medicine Products: